- Home
- IDAI vs CYCN Comparison
IDAI vs CYCN Comparison
Compare IDAI & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- CYCN
- Stock Information
- Founded
- IDAI 2016
- CYCN 2018
- Country
- IDAI United States
- CYCN United States
- Employees
- IDAI N/A
- CYCN N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- CYCN Health Care
- Exchange
- IDAI Nasdaq
- CYCN Nasdaq
- Market Cap
- IDAI 7.7M
- CYCN 8.0M
- IPO Year
- IDAI N/A
- CYCN N/A
- Fundamental
- Price
- IDAI $2.86
- CYCN $2.50
- Analyst Decision
- IDAI
- CYCN
- Analyst Count
- IDAI 0
- CYCN 0
- Target Price
- IDAI N/A
- CYCN N/A
- AVG Volume (30 Days)
- IDAI 25.9K
- CYCN 29.4K
- Earning Date
- IDAI 08-14-2025
- CYCN 08-05-2025
- Dividend Yield
- IDAI N/A
- CYCN N/A
- EPS Growth
- IDAI N/A
- CYCN N/A
- EPS
- IDAI N/A
- CYCN N/A
- Revenue
- IDAI $3,366,415.00
- CYCN $2,174,000.00
- Revenue This Year
- IDAI $25.13
- CYCN N/A
- Revenue Next Year
- IDAI $48.09
- CYCN N/A
- P/E Ratio
- IDAI N/A
- CYCN N/A
- Revenue Growth
- IDAI N/A
- CYCN N/A
- 52 Week Low
- IDAI $1.43
- CYCN $1.27
- 52 Week High
- IDAI $18.75
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- IDAI 50.28
- CYCN 49.62
- Support Level
- IDAI $2.85
- CYCN $2.45
- Resistance Level
- IDAI $3.06
- CYCN $2.90
- Average True Range (ATR)
- IDAI 0.17
- CYCN 0.22
- MACD
- IDAI 0.00
- CYCN 0.05
- Stochastic Oscillator
- IDAI 50.63
- CYCN 59.46
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.